Evidence map›Paper›PMID 39998678›Full record

ReviewCancer immunology, immunotherapy : CII2025

Revealing the role of regulatory b cells in cancer: development, function and treatment significance.

Ruyu Ye, Sijia Li, Yuxiao Li, Kaixin Shi, Li Li

Abstract readReview
In one paragraph

Review in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ruyu YeDepartment of Hematology, The Second Hospital of Dalian Medical University, Dalian, People's Republic of China.
Sijia LiDepartment of Hematology, The Second Hospital of Dalian Medical University, Dalian, People's Republic of China.
Yuxiao LiDepartment of Hematology, The Second Hospital of Dalian Medical University, Dalian, People's Republic of China.
Kaixin ShiDepartment of Hematology, The Second Hospital of Dalian Medical University, Dalian, People's Republic of China.
Li LiDepartment of Hematology, The Second Hospital of Dalian Medical University, Dalian, People's Republic of China. lily312@dmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

B cells are essential components of the immune response, primarily recognized for their ability to produce antibodies. However, emerging research reveals their important roles in regulating immune responses and influencing tumor development, independent of antibodies. The connection between tumor progression and alterations in the tumor microenvironment is well-established, as immune infiltrating cells can enhance the survival of tumor cells by modifying their surroundings. Despite this, the majority of studies have focused on T cells and macrophages, creating a gap in our understanding of B cells. Regulatory B cells (Bregs) represent a crucial subpopulation that plays a significant role in maintaining immune balance. They may have a substantial impact on tumor immunity by negatively regulating tumor-infiltrating immune cells. This paper reviews the existing literature on Bregs, examining their development, phenotypes, functions, and the mechanisms through which they exert their regulatory effects. Furthermore, we highlight their potential interventional roles and prognostic significance in cancer therapy. By addressing the current gaps in knowledge regarding Bregs within tumors, we hope to inspire further research that could lead to innovative cancer treatments and improved outcomes for patients.

Indexed as

B-Lymphocytes, RegulatoryNeoplasmsAnimalsHumansImmunotherapyLymphocytes, Tumor-InfiltratingPrognosisTumor MicroenvironmentBreg cellsBreg developmentBreg functionBreg subtypesCancer prognosis

Identifiers

PMID39998678
PMCPMC11861783

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.